ArticleSchizophrenia research2020
Could the antipsychotic chlorpromazine be a potential treatment for SARS-CoV-2?
Article in Schizophrenia research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 14 citations in OpenAlex.
- Chlorpromazine induces hyposalivation by inhibiting muscarinic CaNaunyn-Schmiedeberg's archives of pharmacology · 2026Article
- DRaW: prediction of COVID-19 antivirals by deep learning-an objection on using matrix factorization.BMC bioinformatics · 2023Article
- Chlorpromazine, a Clinically Approved Drug, Inhibits SARS-CoV-2 Nucleocapsid-Mediated Induction of IL-6 in Human Monocytes.Molecules (Basel, Switzerland) · 2022Article
- Early Neurorehabilitation and Recovery from Disorders of Consciousness After Severe COVID-19.Neurocritical care · 2022Article
- Current Insights and Molecular Docking Studies of the Drugs under Clinical Trial as RdRp Inhibitors in COVID-19 Treatment.Current pharmaceutical design · 2022Article
- Sigma-1 Receptor Ligands Chlorpromazine and Trifluoperazine Attenuate CaCell and tissue biology · 2022Article
- Psychotropics and COVID-19: An analysis of safety and prophylaxis.L'Encephale · 2021Article
- Drug design and repurposing with DockThor-VS web server focusing on SARS-CoV-2 therapeutic targets and their non-synonym variants.Scientific reports · 2021Article
- Antihistamine and cationic amphiphilic drugs, old molecules as new tools against the COVID-19?Medical hypotheses · 2021Article
- Repurposing Sigma-1 Receptor Ligands for COVID-19 Therapy?Frontiers in pharmacology · 2020Review
- The Large Action of Chlorpromazine: Translational and Transdisciplinary Considerations in the Face of COVID-19.Frontiers in pharmacology · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.